Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
A Michael LincoffKirstine Brown-FrandsenHelen M ColhounJohn DeanfieldScott S EmersonSille EsbjergSøren Hardt-LindbergG Kees HovinghSteven E KahnRobert F KushnerIldiko LingvayTugce K OralMarie M MichelsenJorge PlutzkyChristoffer W TornøeDonna H Ryannull nullPublished in: The New England journal of medicine (2023)
In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Keyphrases
- cardiovascular disease
- type diabetes
- weight loss
- weight gain
- insulin resistance
- glycemic control
- metabolic syndrome
- high fat diet induced
- heart failure
- atrial fibrillation
- risk factors
- cardiovascular risk factors
- body mass index
- left ventricular
- cardiovascular events
- randomized controlled trial
- clinical trial
- skeletal muscle
- coronary artery disease